Citigroup: Raises Target Price for Bio-Tech-B to HK$500.6, Reiterates "Outperforming the Market" Rating
Citigroup has released a research report that adjusts the valuation based on the latest data. According to the discounted cash flow (DCF) method, the target price for Bio-Tech-B (06990) is raised by 5
![Citigroup: Raises Target Price for Bio-Tech-B to HK$500.6, Reiterates \](https://fs-cms.hexun.com/img/2025-08-19/220980424.png "Citigroup: Raises Target Price for Bio-Tech-B to HK$500.6, Reiterates \")
Citigroup has released a research report that adjusts the valuation based on the latest data. According to the discounted cash flow (DCF) method, the target price for Bio-Tech-B (06990) is raised by 52% from HK$328.4 to HK$500.6, and reiterates an "Outperforming the Market" rating. The report notes that the group's first-quarter medium-term product sales reached RMB 31 million, mainly driven by the sac-TMT push, with the expansion of second-line non-small cell lung cancer (NSCLC) indications expected to further support sales growth in the second half of 2025.